Abstract:AbstractThe mammalian target of rapamycin (mTOR) is centrally involved in cell growth, metabolism, and angiogenesis. While showing clinical efficacy in a subset of tumors, rapamycin and rapalogs are specific and allosteric inhibitors of mTOR complex 1 (mTORC1), but they do not directly inhibit mTOR complex 2 (mTORC2), an emerging player in cancer. Here, we report chemical structure and biological characterization of three pyrazolopyrimidine ATP-competitive mTOR inhibitors, WAY-600, WYE-687, and WYE-354 (IC50, 5–9 nmol/L), with significant selectivity over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold). Unlike the rapalogs, these inhibitors acutely blocked substrate phosphorylation by mTORC1 and mTORC2 in vitro and in cells in response to growth factor, amino acids, and hyperactive PI3K/AKT. Unlike the inhibitors of PI3K or dual-pan PI3K/mTOR, cellular inhibition of P-S6K1(T389) and P-AKT(S473) by the pyrazolopyrimidines occurred at significantly lower inhibitor concentrations than those of P-AKT(T308) (PI3K-PDK1 readout), showing mTOR selectivity in cellular setting. mTOR kinase inhibitors reduced AKT downstream function and inhibited proliferation of diverse cancer cell lines. These effects correlated with a strong G1 cell cycle arrest in both the rapamycin-sensitive and rapamycin-resistant cells, selective induction of apoptosis, repression of global protein synthesis, and down-regulation of angiogenic factors. When injected into tumor-bearing mice, WYE-354 inhibited mTORC1 and mTORC2 and displayed robust antitumor activity in PTEN-null tumors. Together, our results highlight mechanistic differentiation between rapalogs and mTOR kinase inhibitors in targeting cancer cell growth and survival and provide support for clinical development of mTOR kinase inhibitors as new cancer therapy. [Cancer Res 2009;69(15):OF6232–9]

Structure of prolylrapamycin: confirmation through a revised and detailed NMR assignment study

41-Azido-41-deoxyrapamycin

Separation and identification of Rap-D1,the isomer of sirolimus

Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis

Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis.

Isolation, Structure Determination and Biological Activity of 15-Deoxo-7,32-o-didesmethylrapamycin from the Soil Actinomycete Ll-D45042

Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids As Mtor Targeted Anti-cancer Agents

Comparative analysis of rapamycin biosynthesis clusters between Actinoplanes sp. N902-109 and Streptomyces hygroscopicus ATCC29253

Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used As Potential Mtor‐targeted Anticancer Agents

43-O-(β-d-glucoside)-rapamycin, a Microbial Conversion Product by Bacillus Subtilis CGMCC7764

14-deoxorapamycin, the microbial conversion product of rapamycin by Micromonospora chersina FIM03-712

Synthesis and Anticancer Activity of Novel Rapamycin C-28 Containing Triazole Moiety Compounds

ATP-competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines.

7-O-ethyl-rapamycin produced by rapamycin producing strain mutant FC904-107

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Isolation and structure of homotemsirolimuses A, B, and C.

Discovery and Optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2h)-ones As Potent and Selective ATP-competitive Inhibitors of the Mammalian Target of Rapamycin (Mtor)

A Curvilinear-Path Umbrella Sampling Approach to Characterizing the Interactions Between Rapamycin and Three FKBP12 Variants

Structural Investigation Of Ribosomally Synthesized Natural Products By Hypothetical Structure Enumeration And Evaluation Using Tandem Ms

Isolation and identification of rapamycin dialdehyde

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A